CoChat

Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo

Lamensdorf, Itschak, Youdim, Moussa B. H., Finberg, John P. M. · 1996 · Journal of Neurochemistry
Cited by 131

The DOI matches its Crossref record.

Abstract

Acute inhibition of monoamine oxidase B (MAO‐B) in the rat does not affect striatal dopamine (DA) metabolism, but chronic MAO‐B inhibition with deprenyl has been reported to increase the release of striatal DA, as shown using in vitro techniques. To see whether chronic MAO‐B inhibition also causes an increase in DA release in vivo, rats were treated for 21 days with either deprenyl (0.25 mg/kg), TVP‐1012 [R(+)‐N‐propargyl‐1‐aminoindan mesylate; 0.05 mg/kg), an irreversible inhibitor of MAO‐B that is not metabolized to amphetamines, clorgyline (0.2 mg/kg), or saline (all doses once daily by subcutaneous injection). Concentric 4‐mm‐long microdialysis probes were implanted in the left striatum under pentobarbital/chloral hydrate anesthesia on day 21, and microdialysate DA, 3,4‐dihydroxyacetic acid (DOPAC), and 4‐hydroxy‐3‐methoxyphenyl acetic acid (HVA) were determined in the conscious animals on day 22. Baseline levels of DA were as follows: control, 0.34 ± 0.04 (n = 13); deprenyl, 0.88 ± 0.10 (n = 8, p < 0.01); TVP‐1012, 0.94 ± 0.20 (n = 7, p < 0.01); clorgyline, 0.90 ± 0.12 (n = 7, p < 0.01) pmol/20 min. Levels of DOPAC and HVA were reduced only in the clorgyline‐treated group. The incremental release of DA induced by depolarizing concentration of K+ (100 m M bolus of KCl in perfusate) was significantly greater in clorgyline‐ and deprenyl‐treated rats and elevated (nonsignificantly) in TVP‐1012‐treated rats. Chronic treatment with the MAO‐B inhibitors reduced striatal MAO‐B activity by 90%, with 15% (TVP‐1012) or 40% (deprenyl) inhibition of MAO‐A. Clorgyline inhibited MAO‐A by 95%, with 30% inhibition of MAO‐B. A single dose of deprenyl (0.25 mg/kg, 24 h before microdialysis) had no significant effect on striatal efflux of DA. The results show that DA metabolism was reduced only by clorgyline, whereas neuronal release of DA was enhanced by both MAO‐A and MAO‐B inhibitors on chronic administration. The enhanced DA release by chronic MAO‐B inhibition does not appear to be dependent on production of amphetamine‐like metabolites of the inhibitor. Possible mechanisms for the release‐enhancing effect of the MAO‐B inhibitors include elevation in levels of endogenous β‐phenylethylamine, or an inhibition of DA reuptake, which develops only on chronic administration, because both deprenyl and TVP‐1012 have only very weak effects on amine uptake in acute experiments.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1471-4159.1996.67041532.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 131

Metadata

Authors
Lamensdorf, I., Youdim, M. B. H., & Finberg, J. P. M.
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
1996-10
Volume
67
Issue
4
Pages
1532-1539
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W2104795285
Cited by
131
References
0
FWCI
1.08
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo. https://app.cochat.ai/papers/10.1046/j.1471-4159.1996.67041532.x
The paper
Lamensdorf, I., Youdim, M. B. H., & Finberg, J. P. M. (1996). Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.1996.67041532.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.